IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells

BACKGROUND: In a recent phase II clinical trial for HNSCC patients, IRX-2, a cell-derived biologic, promoted T-cell infiltration into the tumor and prolonged overall survival. Mechanisms responsible for these IRX-2-mediated effects are unknown. We hypothesized that IRX-2 enhanced tumor antigen-(TA)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilling, Bastian, Harasymczuk, Malgorzata, Schuler, Patrick, Egan, James, Ferrone, Soldano, Whiteside, Theresa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567103/
https://www.ncbi.nlm.nih.gov/pubmed/23408925
http://dx.doi.org/10.1371/journal.pone.0047234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567103/
https://www.ncbi.nlm.nih.gov/pubmed/23408925
http://dx.doi.org/10.1371/journal.pone.0047234

Ejemplares similares